Rep. David Taylor Buys Shares of Amgen Inc. (NASDAQ:AMGN)

Representative David Taylor (Republican-Ohio) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on June 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Amgen stock on June 5th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SARDINIA READY MIX 401(K) – DAVE” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of American Electric Power (NASDAQ:AEP) on 6/5/2026.
• Sold $1,001 – $15,000 in shares of Lam Research (NASDAQ:LRCX) on 6/5/2026.
• Purchased $1,001 – $15,000 in shares of Kroger (NYSE:KR) on 6/5/2026.
• Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 6/5/2026.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 6/5/2026.
• Purchased $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 6/5/2026.
• Purchased $1,001 – $15,000 in shares of Medpace (NASDAQ:MEDP) on 5/15/2026.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 5/15/2026.
• Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 5/15/2026.
• Purchased $1,001 – $15,000 in shares of AT&T (NYSE:T) on 5/15/2026.

Amgen Stock Up 1.3%

AMGN stock opened at $351.64 on Thursday. The stock has a market capitalization of $189.78 billion, a P/E ratio of 24.47, a price-to-earnings-growth ratio of 3.48 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29. The firm has a 50-day moving average price of $340.45 and a 200-day moving average price of $345.95.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities research analysts anticipate that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AMGN. Wells Fargo & Company increased their price target on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. Royal Bank Of Canada reaffirmed a “positive” rating on shares of Amgen in a report on Thursday, June 18th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Jefferies Financial Group assumed coverage on Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target on the stock. Finally, Canaccord Genuity Group began coverage on Amgen in a research note on Monday, April 20th. They issued a “hold” rating and a $366.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $354.42.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.85% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Amgen

A number of institutional investors have recently made changes to their positions in AMGN. Dogwood Wealth Management LLC boosted its stake in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the last quarter. Anfield Capital Management LLC boosted its position in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the last quarter. Board of the Pension Protection Fund acquired a new stake in Amgen during the 4th quarter worth about $26,000. Tower View Wealth Management LLC grew its holdings in Amgen by 331.6% during the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares during the period. Finally, Manning & Napier Advisors LLC lifted its stake in shares of Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the period. Institutional investors own 76.50% of the company’s stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.